BioRestorative Therapies Inc (BRTX) - Total Liabilities
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) has total liabilities worth $3.44 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BRTX operating cash flow to assess how effectively this company generates cash.
BioRestorative Therapies Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how BioRestorative Therapies Inc's total liabilities have evolved over time, based on quarterly financial data. Check BRTX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
BioRestorative Therapies Inc Competitors by Total Liabilities
The table below lists competitors of BioRestorative Therapies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korab Resources Ltd
AU:KOR
|
Australia | AU$4.53 Million |
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
USA | $10.19 Million |
|
Keystone Law Group PLC
LSE:KEYS
|
UK | GBX27.14 Million |
|
Greenwave Technology Solutions Inc. Common Stock
NASDAQ:GWAV
|
USA | $25.99 Million |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
Sweden | Skr1.25 Million |
|
Baillie Gifford China Growth Trust PLC
LSE:BGCG
|
UK | GBX8.36 Million |
|
Enveric Biosciences Inc
NASDAQ:ENVB
|
USA | $905.88K |
|
Fonix Mobile plc
LSE:FNX
|
UK | GBX47.45 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down BioRestorative Therapies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BioRestorative Therapies Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioRestorative Therapies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioRestorative Therapies Inc (2009–2024)
The table below shows the annual total liabilities of BioRestorative Therapies Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.75 Million | +43.76% |
| 2023-12-31 | $2.61 Million | -57.57% |
| 2022-12-31 | $6.14 Million | +617.38% |
| 2021-12-31 | $856.50K | -84.92% |
| 2020-12-31 | $5.68 Million | -60.13% |
| 2019-12-31 | $14.24 Million | +44.84% |
| 2018-12-31 | $9.83 Million | +14.41% |
| 2017-12-31 | $8.60 Million | +30.62% |
| 2016-12-31 | $6.58 Million | +11.05% |
| 2015-12-31 | $5.93 Million | -30.94% |
| 2014-12-31 | $8.58 Million | +6.35% |
| 2013-12-31 | $8.07 Million | +25.87% |
| 2012-12-31 | $6.41 Million | +64.04% |
| 2011-12-31 | $3.91 Million | +222.20% |
| 2010-12-31 | $1.21 Million | +297.62% |
| 2009-12-31 | $305.00K | -- |
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more